NURIX THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
NURIX THERAPEUTICS, INC. (NRIX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 16.25 million shares for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-02-28 was 16.27M shares, a 13.82% increase year-over-year.
- NURIX THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-02-28 was 14.30M shares, a 16.14% increase year-over-year.
- NURIX THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-02-29 was 12.31M shares, a 9.43% increase year-over-year.
- NURIX THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-02-28 was 11.25M shares, a 54.37% increase year-over-year.
- NURIX THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 13.80M shares, a 16.32% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 11.87M shares, a 21.15% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 9.80M shares, a 6.62% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 9.19M shares, a 52.91% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-05-31 | 16.25M shares 10-Q · filed 2026-07-09 | |||
| 2026-02-28 | 16.27M shares 10-Q · filed 2026-04-08 | |||
| 2025-11-30 | 13.80M shares 10-K · filed 2026-01-28 | |||
| 2025-08-31 | 14.59M shares 10-Q · filed 2025-10-09 | |||
| 2025-05-31 | 14.75M shares 10-Q · filed 2026-07-09 | |||
| 2025-02-28 | 14.30M shares 10-Q · filed 2026-04-08 | |||
| 2024-11-30 | 11.87M shares 10-K · filed 2026-01-28 | |||
| 2024-08-31 | 12.01M shares 10-Q · filed 2025-10-09 | |||
| 2024-05-31 | 12.19M shares 10-Q · filed 2025-07-09 | |||
| 2024-02-29 | 12.31M shares 10-Q · filed 2025-04-08 | |||
| 2023-11-30 | 9.80M shares 10-K · filed 2026-01-28 | |||
| 2023-08-31 | 10.13M shares 10-Q · filed 2024-10-11 | |||
| 2023-05-31 | 10.55M shares 10-Q · filed 2024-07-11 | |||
| 2023-02-28 | 11.25M shares 10-Q · filed 2024-04-10 | |||
| 2022-11-30 | 9.19M shares 10-K · filed 2025-01-28 | |||
| 2022-08-31 | 9.02M shares 10-Q · filed 2023-10-12 | |||
| 2022-05-31 | 7.23M shares 10-Q · filed 2023-07-13 | |||
| 2022-02-28 | 7.29M shares 10-Q · filed 2023-04-13 | |||
| 2021-11-30 | 6.01M shares 10-K · filed 2023-02-09 | |||
| 2021-08-31 | 5.73M shares 10-Q · filed 2021-10-14 | 5.73M shares 10-Q · filed 2022-10-06 | ||
| 2021-05-31 | 5.28M shares 10-Q · filed 2021-07-13 | 5.28M shares 10-Q · filed 2022-07-07 | ||
| 2021-02-28 | 5.25M shares 10-Q · filed 2022-04-08 | |||
| 2020-11-30 | 4.59M shares 10-K · filed 2022-01-28 | |||
| 2020-08-31 | 3.69M shares 10-Q · filed 2021-10-14 | 3.69M shares 10-Q · filed 2021-10-14 | ||
| 2020-05-31 | 23.50M shares 10-Q · filed 2021-07-13 | 25.28M shares 10-Q · filed 2021-07-13 | ||
| 2020-02-29 | 15.56M shares 10-Q · filed 2021-04-13 | |||
| 2019-11-30 | 14.87M shares 10-K · filed 2022-01-28 | |||
| 2019-08-31 | 14.76M shares 10-Q · filed 2020-10-14 | 14.76M shares 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |